A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

The Master RAD Protocol is based on the concept that optimal suppression of viral load in vivo will be achieved in patients with rapidly progressing or advanced HIV disease (RAD) using antiretroviral combinations inhibiting viral replication at distinct sites of action. Antiretroviral combinations are chosen with the hypothesis that simultaneous change to as many new agents as possible is necessary to maximally reduce plasma viral load.

In this open-label, multicenter study patients are randomized into 1 of 4 groups based on prior antiretroviral experience. Each regimen consists of 4 drugs...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Your child may be eligible for this study if he or she:
• • Is HIV-positive.
• • Is between the ages of 6 months and 21 years (consent of parent or guardian required if under 18).
• • Has an HIV blood level above 50,000 copies/mL on 2 consecutive occasions, while taking anti-HIV therapy.
• • Has advanced HIV disease or disease progression while receiving 8 weeks or more of continuous unchanged anti-HIV therapy.
• • Is able to receive at least one of the following: RTV, NVP, or NFV.
• • Exclusion Criteria
• Your child will not be eligible for this study if he or she:
• • Is receiving treatment for a serious bacterial, viral, or opportunistic (HIV-associated) infection within 14 days prior to study entry.
• • Has a history of pancreatitis or peripheral neuropathy.
• • Has cancer requiring chemotherapy.
• • Is allergic to the study medications.
• • Is taking certain medications.
• • Is pregnant.